NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Cognitive, Neuro & Sleep/Noopept

Noopept

Dipeptide-derived nootropic (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia; animal literature with limited human trials.

Overview

Noopept (also known as GVS-111) is a synthetic dipeptide-based nootropic, chemically N-phenylacetyl-L-prolylglycine ethyl ester, developed in Russia in the 1990s. It is derived from the structure of the endogenous peptide cycloprolylglycine and is described in its originating literature as enhancing memory and having neuroprotective properties. Most published mechanistic work comes from animal models, and it is used clinically in some post-Soviet countries, but large peer-reviewed human trials in the international literature are lacking.

Mechanism

The proposed mechanisms are not fully established. Animal studies report effects consistent with modulation of glutamatergic and cholinergic systems, increases in brain-derived neurotrophic factor or NGF-related signaling, and antioxidant-type actions. It is orally bioavailable and crosses the blood-brain barrier, and its acid metabolite is also reported to be active.

Dosing

In the originating clinical practice and animal literature, noopept is given orally, typically in milligram-range doses (single-digit to low tens of milligrams) per day; rodent studies use protocol-specific doses. Figures should be sourced from the primary literature, and products from unregulated suppliers carry quality risks.

Expected Effects

  • improved memory-related performance in rodent behavioral studies
  • neuroprotective effects in animal models of various insults
  • subjective cognitive benefits reported in some small human studies and clinical practice

Side Effects & Tolerability

Published data describe generally good tolerability with occasional headache, irritability, or gastrointestinal upset. Systematic long-term safety data from large controlled human trials are not available.

Storage

Noopept is a stable small-molecule powder; research-grade material should be stored per the supplier label, typically cool, dry, and protected from light and moisture.

Related peptides

BDNF Mimetic PeptidesGeneric category of peptides promoted as BDNF mimetics; specific products are not identified in the literature.Blood-Brain Barrier Peptide AnalogsCatalog name implying peptides that cross or act at the blood-brain barrier; no specific products are defined in the literature.Central Pain Pathway Modulator AnalogsUmbrella catalog name implying peptides acting on central pain processing; no specific compounds are documented.Cerebrolysin Peptide FractionPharmaceutical preparation of low-molecular-weight peptides derived from porcine brain, approved in some countries for dementia and stroke recovery.CNTF AnalogsCategory of products sold as CNTF-related peptides; CNTF and its clinical analog Axokine are real, but these items are not documented.ConolidineMonoterpene indole alkaloid from Tabernaemontana divaricata studied as a candidate non-opioid analgesic; a small molecule, not a peptide.